Fig 1: CEBPB knockdown triggers anti-inflammatory M2-like polarization of macrophages. (A) RT-qPCR for verifying the expression of CEBPB in macrophages transfected with siRNAs targeting CEBPB. (B–F) RT-qPCR for quantifying the expression of CEBPB, M1-type marker (iNOS), and M2-type markers (including FIZZ1, Ym1, and Arg1) in macrophages treated with IFN-?, and LPS, IL-4, or CEBPB knockdown. (G–L) Western blotting for evaluating the expression of CEBPB, M1-type marker (iNOS), and M2-type markers (including FIZZ1, Ym1, and Arg1) in macrophages treated with IFN-?, and LPS, IL-4, or CEBPB knockdown. (M–O) ELISA detecting the levels of TNF-a, IL-6, and IL-1ß in the supernatant of macrophages. Compared with control, *p < 0.05; **p < 0.01; ***p < 0.001; ****p < 0.0001. Compared with IFN-? and LPS, ### p < 0.001; #### p < 0.0001. Compared with IL-4, @ p < 0.05; @@ p < 0.01; @@@ p < 0.001; @@@@ p < 0.0001.